Ipca Laboratories is currently trading at Rs. 451.00, up by 0.90 points or 0.20% from its previous closing of Rs. 450.10 on the BSE.
The scrip opened at Rs. 453.95 and has touched a high and low of Rs. 456.75 and Rs. 449.95 respectively. So far 4331 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 495.00 on 01-Oct-2012 and a 52 week low of Rs. 234.05 on 23-Nov-2011.
Last one week high and low of the scrip stood at Rs. 477.00 and Rs. 449.00 respectively. The current market cap of the company is Rs. 5678.03 crore.
The promoters holding in the company stood at 45.91% while Institutions and Non-Institutions held 33.80% and 20.29% respectively.
Credit rating agency, CRISIL has reaffirmed AA rating to Ipca Laboratories’ long term bank facilities. The rating agency has also reaffirmed A1+ rating to the company’s Rs 1.5 billion short term debt while, the rating agency has reaffirmed AA/ stable rating to the company’s Rs 500 million Non Convertible Debentures (NCDs).
Further, CRISIL has assigned AA/stable rating to Rs 2,000 million NCDs of the company.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1814.50 |
Dr. Reddys Lab | 1340.80 |
Cipla | 1476.45 |
Lupin | 2160.20 |
Zydus Lifesciences | 972.95 |
View more.. |